TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02691702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB118
Description: Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
Study: NCT02033915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive discussion group
Description: The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
Study: NCT02474745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: - Directed open-glottis pushing
Description: Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Directed closed-glottis pushing
Description: Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible.
Study: NCT02472808

Intervention type: OTHER
Group type: OTHER
Intervention: cTBNA without ROSE
Description: Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
Study: NCT02696291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Study: NCT03660995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.
Description: Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.
Description: Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child.
Study: NCT03280810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement group
Description: Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
Study: NCT03606785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injection
Description: The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: patients will receive a placebo of 100 mL 0.9% normal saline
Study: NCT01149863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
Study: NCT02676882

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EnBrace HR
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EnBrace HR
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
Study: NCT03617666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
Study: NCT01772329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Routine Care. No Cognitive Therapy Intervention
Study: NCT01482416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens, Conjugated (USP)
Description: Experimental group will use 0.625mg/day during 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will use placebo once/day during 30 days
Study: NCT04904211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based chemotherapy
Description: To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
Study: NCT03485144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV003
Description: Live attenuated virus vaccine-TetraVax-DV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TV003
Description: Placebo
Study: NCT02018419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
Study: NCT01935765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the autonomous nervous system
Description: blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the autonomous nervous system
Description: blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination of the sleep
Description: Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination of the sleep
Description: Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination of diabetology
Description: history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological dosages
Description: Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological dosages
Description: Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG)
Description: Electrocardiogram (ECG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG)
Description: Electrocardiogram (ECG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid echography
Description: Carotid echography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid echography
Description: Carotid echography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure
Study: NCT04076644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS treatment
Description: TMS using either a standard 10hz 20min or 3 min theta burst protocol
Study: NCT04208906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo O3
Description: After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2.
Study: NCT03342976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My-AHA platform
Description: ICT strategy for early detection of frailties

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: My-AHA platform
Description: ICT strategy for early detection of frailties
Study: NCT03491618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAIN REDUCTION ON VAS/NRS
Description: Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAIN REDUCTION ON VAS/NRS
Description: Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
Study: NCT01892930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo partial or radical nephrectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04433468

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
Study: NCT00720941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg administered once daily orally continuous dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
Study: NCT02121587

Intervention type: BEHAVIORAL
Intervention: Pain self-management course
Description: This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
Study: NCT03026257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses with added wetting agent
Description: Silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samfilcon A contact lenses
Description: Habitual silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent
Description: Multi-purpose disinfecting solution for contact lens care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide-based contact lens solution with added wetting agent
Description: Solution for contact lens cleaning and disinfecting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon C contact lenses
Description: Habitual silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Habitual silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Multi-Purpose Solution (HMPS)
Description: Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
Study: NCT00417794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strattera
Description: escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
Study: NCT01190254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine 2.5 mg
Description: asenapine 2.5 mg tablets for sublingual administration
Study: NCT02472808

Intervention type: OTHER
Group type: OTHER
Intervention: cTBNA with ROSE
Description: Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: EBUS-TBNA without ROSE
Description: Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: EBUS-TBNA with ROSE
Description: Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
Study: NCT00351611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica (pregabalin)
Description: 150 mg twice a day, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Twice a day, oral administration
Study: NCT00017095

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: microarray analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT02730975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA Reduced dose-normal diet (A)
Description: Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA reduced dose-fat diet (B)
Description: Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
Study: NCT00017095

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04965805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold plasmaJet kINPen Med
Description: experimental, non-inferiority

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best practice wound dressings
Description: comparative,
Study: NCT05260294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural space identification with cervical epidural steroid injection employing CST and LORT.
Description: Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural space identification with cervical epidural steroid injection employing CST and LORT.
Description: Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
Study: NCT00573378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-a2b
Description: Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.